Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | IDH1 act mut |
Therapy | Ivosidenib |
Indication/Tumor Type | low grade glioma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
IDH1 act mut | low grade glioma | predicted - sensitive | Ivosidenib | Clinical Study | Actionable | In a retrospective analysis, Tibsovo (ivosidenib) treatment was well tolerated in patients with glioma harboring an IDH1 mutation, and resulted in a partial response in 13.6% (3/22), minor response in 22.7% (5/22), and stable disease in 54.5% (12/22) of patients with nonenhancing disease, and stable disease in 62.5% (5/8) of patients with enhancing disease (PMID: 38496920). | 38496920 |
PubMed Id | Reference Title | Details |
---|---|---|
(38496920) | Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma. | Full reference... |